1018 ISS
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- 1018 ISS
- 1018 iss
- 1018 ISS
- 1018 ISS [WHO-DD]
- 1018 iss who dd
- cpg 1018
- Cpg 1018
- CpG 1018
- CpG 1018®
- cpg oligonucleotide 1018 iss
- Cpg oligonucleotide 1018 iss
- CPG-1018
- dna d p thio t g a c t g t g a a c g t t c g a g a t g a
- DNA, D(P-THIO)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A)
- iss 1018
- Iss 1018
- iss 1018 cpg oligodeoxynucleotide
- Iss 1018 cpg oligodeoxynucleotide
- Iss-1018
- CAS registry numbers
- 937402-51-2
- ChEMBL ID
- CHEMBL4297680
- FDA ingredient codes (UNII)
- 25DT549L0G
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Toll-like receptor 9 agonist
- Action type
- Agonist
- Target
- Toll-like receptor 9
- Protein identifier
- Q9NR96
Open Targets mechanisms
- Mechanism
- Toll-like receptor 9 agonist
- Action type
- Agonist
- Target
- Toll-like receptor 9
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004197
- Subject identifier
- D019694
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004197
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT00251394
- NCT00403052
- NCT00426712
- NCT00498212
- NCT04177355
- NCT04405908
- NCT04672395
- NCT05012787
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (9)
- A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
- A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
- A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
- Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
- Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
- Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
- Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
- SCB-2019 as COVID-19 Vaccine
- Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
In development for (6)
- Colorectal neoplasm Phase 1
- COVID-19 Phase 3
- Hepatitis B virus infection Phase 2
- HIV infectious disease Phase 1
- Lymphoma Phase 3
- Non-Hodgkin lymphoma Phase 2
Targets (1)
- TLR9 Toll-like receptor 9 agonist